DOW
47
4
STT
48
4
XEL
48
11
TAP
57
6
NTRS
35
10
VFC
56
6
MDLZ
28
2
PNW
55
3
ACN
54
2
SLB
41
2
HCP
54
2
AA
27
5
TSCO
42
4
M
40
3
ABBV
40
5
FSLR
50
6
CSCO
63
5
MO
47
6
PEP
33
4
HBAN
47
7
DOW
47
4
STT
48
4
XEL
48
11
TAP
57
6
NTRS
35
10
VFC
56
6
MDLZ
28
2
PNW
55
3
ACN
54
2
SLB
41
2
HCP
54
2
AA
27
5
TSCO
42
4
M
40
3
ABBV
40
5
FSLR
50
6
CSCO
63
5
MO
47
6
PEP
33
4
HBAN
47
7
Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

How to Turn the AI Energy Crisis into BIG Profits

And investors who move now into one technology could make a whole lot of money.
Sell
6

DNLI
Denali Therapeutics

Last Price:
$21.48
Seasonality Move:
-13.89%

7 Day Trial

ALL ACCESS PASS

$ 7

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.

Denali Therapeutics Price Quote

$21.48
+0.02 (+-0.05%)
(Updated: December 21, 2024 at 5:23 AM ET)

Denali Therapeutics Key Stats

Sell
6
Denali Therapeutics (DNLI) is a Sell
Day range:
$21.00 - $22.21
52-week range:
$14.56 - $33.33
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
9.85
P/B ratio:
2.34%
Volume:
2.5M
Avg. volume:
978.4K
1-year change:
1.37%
Market cap:
$3.1B
Revenue:
$330.5M
EPS:
$-2.76

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Data Unavailable

Is Denali Therapeutics Cash Flow Positive?

Data Unavailable

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Data Unavailable

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.3%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 42.77
Upside from Last Price: 99.3%

Major Shareholders

Data Unavailable